Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
-
As I’m sure you know, times are tough. Wages have largely remained the same while prices have risen across the board – and healthcare is no ...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment